Document is current

Article History

Received: 4 February 2022

Accepted: 9 September 2022

First Online: 24 October 2022

Declarations

:

: The DKTK MASTER trial was approved by Heidelberg and Berlin local ethics committees. Written, informed consent was obtained from all patients prior to inclusion in the study.

: Not applicable.

: Damian Rieke is a consultant for Alacris Theranostics GmbH and received honoraria from Bristol-Myers Squibb and Bayer. Peter Horak reported consulting or advisory board membership for Platomics and honoraria from Platomics and Roche. Ivan Jelas has received consultant and/or advisory board and/or speaker fees from Bristol-Myers Squibb, Merck, and Roche. Hanno Glimm received research funding from Bayer and travel/accommodation/expenses support from Illumina. Albrecht Stenzinger: advisory board/speaker’s bureau—Aignostics, Astra Zeneca, AGCT, Bayer, BMS, Eli Lilly, Illumina, Incyte, Janssen, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda, Thermo Fisher; research grants—Bayer, BMS, Chugai, and Incyte.Stefan Fröhling: consulting or advisory board membership—Bayer, Illumina, and Roche; honoraria—Amgen, Eli Lilly, PharmaMar, and Roche; research funding—AstraZeneca, Pfizer, PharmaMar, Roche; travel or accommodation expenses—Amgen, Eli Lilly, Illumina, PharmaMar, and Roche. Ulrich Keilholz has received advisory board/speaker bureau, trial support, research collaboration, or research support from Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Glycotope, Innate, Lilly, Medimmune, MerckSerono, MSD/Merck, Novartis, Pfizer, Roche/Genentech, and Sirtex. All other authors report not competing interests with regard to this work.